Molecular Partners AG

MOLN

Company Profile

  • Business description

    Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

  • Contact

    Wagistrasse 14
    Schlieren
    Zurich8952
    CHE

    T: +41 447557700

    https://www.molecularpartners.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    159

Stocks News & Analysis

stocks

Palantir earnings: AI leadership intact; valuation still causes heartburn

Our view of Palantir Technologies.
stocks

Market underestimating cheap ASX share

Investors missing the big opportunity in batteries.
stocks

As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally

Demand for AI has catapulted tech stocks into the stratosphere.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,071.2019.30-0.21%
CAC 408,074.236.700.08%
DAX 4024,048.8799.760.42%
Dow JONES (US)47,193.08107.840.23%
FTSE 1009,777.0862.120.64%
HKSE25,935.4116.99-0.07%
NASDAQ23,557.04208.400.89%
Nikkei 22550,212.271,284.93-2.50%
NZX 50 Index13,620.9815.020.11%
S&P 5006,811.8740.320.60%
S&P/ASX 2008,802.007.80-0.09%
SSE Composite Index3,969.259.060.23%

Market Movers